Diamond Hill Capital Management LLC Investment Advisor Buys Shares of 391,340 Perrigo Company plc $PRGO

Diamond Hill Capital Management LLC Investment Advisor bought a new position in Perrigo Company plc (NYSE:PRGO) during the 2nd quarter, HoldingsChannel reports. The firm bought 391,340 shares of the company’s stock, valued at approximately $4,066,000.

Several other institutional investors have also modified their holdings of PRGO. Amundi lifted its stake in Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares in the last quarter. Kestra Investment Management LLC lifted its position in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares during the last quarter. Finally, Covestor Ltd lifted its position in Perrigo by 14.4% during the fourth quarter. Covestor Ltd now owns 8,991 shares of the company’s stock worth $125,000 after acquiring an additional 1,129 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Trading Down 1.2%

NYSE:PRGO opened at $12.89 on Tuesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.32 and a current ratio of 2.32. The firm has a market cap of $1.79 billion, a P/E ratio of -1.03, a P/E/G ratio of 1.49 and a beta of 0.51. The firm’s fifty day moving average is $10.86 and its 200-day moving average is $11.43. Perrigo Company plc has a 52 week low of $9.23 and a 52 week high of $24.60.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm posted ($0.06) EPS. The company’s quarterly revenue was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities analysts expect that Perrigo Company plc will post 2.2 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 9.0%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio is currently -9.27%.

Analysts Set New Price Targets

PRGO has been the subject of a number of recent research reports. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised shares of Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.